Human Vaccines-Europe Market Status and Trend Report 2013-2023
Report Summary
Human Vaccines-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main market players of Human Vaccines in Europe, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the Europe Human Vaccines market as:
Europe Human Vaccines Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Human Vaccines Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
Europe Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
Europe Human Vaccines Market: Players Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Human Vaccines-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Human Vaccines industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Europe and Regional Market Size of Human Vaccines 2013-2017, and development forecast 2018-2023
Main market players of Human Vaccines in Europe, with company and product introduction, position in the Human Vaccines market
Market status and development trend of Human Vaccines by types and applications
Cost and profit status of Human Vaccines, and marketing status
Market growth drivers and challenges
The report segments the Europe Human Vaccines market as:
Europe Human Vaccines Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Germany
United Kingdom
France
Italy
Spain
Benelux
Russia
Europe Human Vaccines Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pneumococcal
Influenza
Hepatitis
HPV
Meningococcal
Rotavirus
Measles
Typhoid
Combination
Europe Human Vaccines Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Pediatrics
Adolescents
Adults
Geriatrics
Europe Human Vaccines Market: Players Segment Analysis (Company and Product introduction, Human Vaccines Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca
Bavarian Nordic
Bharat Biotech
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Mymetics
Novartis AG
Pfizer, Inc.
Sanofi
Shenzhen Kangtai Biological Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF HUMAN VACCINES
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 Europe Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Human Vaccines in Europe 2013-2017
2.2 Consumption Market of Human Vaccines in Europe by Regions
2.2.1 Consumption Volume of Human Vaccines in Europe by Regions
2.2.2 Revenue of Human Vaccines in Europe by Regions
2.3 Market Analysis of Human Vaccines in Europe by Regions
2.3.1 Market Analysis of Human Vaccines in Germany 2013-2017
2.3.2 Market Analysis of Human Vaccines in United Kingdom 2013-2017
2.3.3 Market Analysis of Human Vaccines in France 2013-2017
2.3.4 Market Analysis of Human Vaccines in Italy 2013-2017
2.3.5 Market Analysis of Human Vaccines in Spain 2013-2017
2.3.6 Market Analysis of Human Vaccines in Benelux 2013-2017
2.3.7 Market Analysis of Human Vaccines in Russia 2013-2017
2.4 Market Development Forecast of Human Vaccines in Europe 2018-2023
2.4.1 Market Development Forecast of Human Vaccines in Europe 2018-2023
2.4.2 Market Development Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Human Vaccines in Europe by Types
3.1.2 Revenue of Human Vaccines in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Human Vaccines in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Human Vaccines in Europe by Downstream Industry
4.2 Demand Volume of Human Vaccines by Downstream Industry in Major Countries
4.2.1 Demand Volume of Human Vaccines by Downstream Industry in Germany
4.2.2 Demand Volume of Human Vaccines by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Human Vaccines by Downstream Industry in France
4.2.4 Demand Volume of Human Vaccines by Downstream Industry in Italy
4.2.5 Demand Volume of Human Vaccines by Downstream Industry in Spain
4.2.6 Demand Volume of Human Vaccines by Downstream Industry in Benelux
4.2.7 Demand Volume of Human Vaccines by Downstream Industry in Russia
4.3 Market Forecast of Human Vaccines in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
5.1 Europe Economy Situation and Trend Overview
5.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 6 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Human Vaccines in Europe by Major Players
6.2 Revenue of Human Vaccines in Europe by Major Players
6.3 Basic Information of Human Vaccines by Major Players
6.3.1 Headquarters Location and Established Time of Human Vaccines Major Players
6.3.2 Employees and Revenue Level of Human Vaccines Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca
7.1.1 Company profile
7.1.2 Representative Human Vaccines Product
7.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
7.2 Bavarian Nordic
7.2.1 Company profile
7.2.2 Representative Human Vaccines Product
7.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
7.3 Bharat Biotech
7.3.1 Company profile
7.3.2 Representative Human Vaccines Product
7.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
7.4 CSL Limited
7.4.1 Company profile
7.4.2 Representative Human Vaccines Product
7.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
7.5 Emergent BioSolutions, Inc.
7.5.1 Company profile
7.5.2 Representative Human Vaccines Product
7.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
7.6 GlaxoSmithKline plc
7.6.1 Company profile
7.6.2 Representative Human Vaccines Product
7.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.7 Johnson & Johnson
7.7.1 Company profile
7.7.2 Representative Human Vaccines Product
7.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.8 Merck & Co., Inc.
7.8.1 Company profile
7.8.2 Representative Human Vaccines Product
7.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.9 Mymetics
7.9.1 Company profile
7.9.2 Representative Human Vaccines Product
7.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Human Vaccines Product
7.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer, Inc.
7.11.1 Company profile
7.11.2 Representative Human Vaccines Product
7.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.12 Sanofi
7.12.1 Company profile
7.12.2 Representative Human Vaccines Product
7.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
7.13 Shenzhen Kangtai Biological Products Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Human Vaccines Product
7.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
7.14 Takeda Pharmaceutical Company Limited.
7.14.1 Company profile
7.14.2 Representative Human Vaccines Product
7.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
8.1 Industry Chain of Human Vaccines
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
9.1 Cost Structure Analysis of Human Vaccines
9.2 Raw Materials Cost Analysis of Human Vaccines
9.3 Labor Cost Analysis of Human Vaccines
9.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 10 MARKETING STATUS ANALYSIS OF HUMAN VACCINES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Human Vaccines in This Report
1.2 Commercial Types of Human Vaccines
1.2.1 Pneumococcal
1.2.2 Influenza
1.2.3 Hepatitis
1.2.4 HPV
1.2.5 Meningococcal
1.2.6 Rotavirus
1.2.7 Measles
1.2.8 Typhoid
1.2.9 Combination
1.3 Downstream Application of Human Vaccines
1.3.1 Pediatrics
1.3.2 Adolescents
1.3.3 Adults
1.3.4 Geriatrics
1.4 Development History of Human Vaccines
1.5 Market Status and Trend of Human Vaccines 2013-2023
1.5.1 Europe Human Vaccines Market Status and Trend 2013-2023
1.5.2 Regional Human Vaccines Market Status and Trend 2013-2023
CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Human Vaccines in Europe 2013-2017
2.2 Consumption Market of Human Vaccines in Europe by Regions
2.2.1 Consumption Volume of Human Vaccines in Europe by Regions
2.2.2 Revenue of Human Vaccines in Europe by Regions
2.3 Market Analysis of Human Vaccines in Europe by Regions
2.3.1 Market Analysis of Human Vaccines in Germany 2013-2017
2.3.2 Market Analysis of Human Vaccines in United Kingdom 2013-2017
2.3.3 Market Analysis of Human Vaccines in France 2013-2017
2.3.4 Market Analysis of Human Vaccines in Italy 2013-2017
2.3.5 Market Analysis of Human Vaccines in Spain 2013-2017
2.3.6 Market Analysis of Human Vaccines in Benelux 2013-2017
2.3.7 Market Analysis of Human Vaccines in Russia 2013-2017
2.4 Market Development Forecast of Human Vaccines in Europe 2018-2023
2.4.1 Market Development Forecast of Human Vaccines in Europe 2018-2023
2.4.2 Market Development Forecast of Human Vaccines by Regions 2018-2023
CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Europe Market Status by Types
3.1.1 Consumption Volume of Human Vaccines in Europe by Types
3.1.2 Revenue of Human Vaccines in Europe by Types
3.2 Europe Market Status by Types in Major Countries
3.2.1 Market Status by Types in Germany
3.2.2 Market Status by Types in United Kingdom
3.2.3 Market Status by Types in France
3.2.4 Market Status by Types in Italy
3.2.5 Market Status by Types in Spain
3.2.6 Market Status by Types in Benelux
3.2.7 Market Status by Types in Russia
3.3 Market Forecast of Human Vaccines in Europe by Types
CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Human Vaccines in Europe by Downstream Industry
4.2 Demand Volume of Human Vaccines by Downstream Industry in Major Countries
4.2.1 Demand Volume of Human Vaccines by Downstream Industry in Germany
4.2.2 Demand Volume of Human Vaccines by Downstream Industry in United Kingdom
4.2.3 Demand Volume of Human Vaccines by Downstream Industry in France
4.2.4 Demand Volume of Human Vaccines by Downstream Industry in Italy
4.2.5 Demand Volume of Human Vaccines by Downstream Industry in Spain
4.2.6 Demand Volume of Human Vaccines by Downstream Industry in Benelux
4.2.7 Demand Volume of Human Vaccines by Downstream Industry in Russia
4.3 Market Forecast of Human Vaccines in Europe by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF HUMAN VACCINES
5.1 Europe Economy Situation and Trend Overview
5.2 Human Vaccines Downstream Industry Situation and Trend Overview
CHAPTER 6 HUMAN VACCINES MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE
6.1 Sales Volume of Human Vaccines in Europe by Major Players
6.2 Revenue of Human Vaccines in Europe by Major Players
6.3 Basic Information of Human Vaccines by Major Players
6.3.1 Headquarters Location and Established Time of Human Vaccines Major Players
6.3.2 Employees and Revenue Level of Human Vaccines Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 HUMAN VACCINES MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 AstraZeneca
7.1.1 Company profile
7.1.2 Representative Human Vaccines Product
7.1.3 Human Vaccines Sales, Revenue, Price and Gross Margin of AstraZeneca
7.2 Bavarian Nordic
7.2.1 Company profile
7.2.2 Representative Human Vaccines Product
7.2.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bavarian Nordic
7.3 Bharat Biotech
7.3.1 Company profile
7.3.2 Representative Human Vaccines Product
7.3.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Bharat Biotech
7.4 CSL Limited
7.4.1 Company profile
7.4.2 Representative Human Vaccines Product
7.4.3 Human Vaccines Sales, Revenue, Price and Gross Margin of CSL Limited
7.5 Emergent BioSolutions, Inc.
7.5.1 Company profile
7.5.2 Representative Human Vaccines Product
7.5.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Emergent BioSolutions, Inc.
7.6 GlaxoSmithKline plc
7.6.1 Company profile
7.6.2 Representative Human Vaccines Product
7.6.3 Human Vaccines Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
7.7 Johnson & Johnson
7.7.1 Company profile
7.7.2 Representative Human Vaccines Product
7.7.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.8 Merck & Co., Inc.
7.8.1 Company profile
7.8.2 Representative Human Vaccines Product
7.8.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
7.9 Mymetics
7.9.1 Company profile
7.9.2 Representative Human Vaccines Product
7.9.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Mymetics
7.10 Novartis AG
7.10.1 Company profile
7.10.2 Representative Human Vaccines Product
7.10.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Novartis AG
7.11 Pfizer, Inc.
7.11.1 Company profile
7.11.2 Representative Human Vaccines Product
7.11.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Pfizer, Inc.
7.12 Sanofi
7.12.1 Company profile
7.12.2 Representative Human Vaccines Product
7.12.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Sanofi
7.13 Shenzhen Kangtai Biological Products Co., Ltd.
7.13.1 Company profile
7.13.2 Representative Human Vaccines Product
7.13.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Shenzhen Kangtai Biological Products Co., Ltd.
7.14 Takeda Pharmaceutical Company Limited.
7.14.1 Company profile
7.14.2 Representative Human Vaccines Product
7.14.3 Human Vaccines Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited.
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF HUMAN VACCINES
8.1 Industry Chain of Human Vaccines
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF HUMAN VACCINES
9.1 Cost Structure Analysis of Human Vaccines
9.2 Raw Materials Cost Analysis of Human Vaccines
9.3 Labor Cost Analysis of Human Vaccines
9.4 Manufacturing Expenses Analysis of Human Vaccines
CHAPTER 10 MARKETING STATUS ANALYSIS OF HUMAN VACCINES
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
